Transthyretin Amyloidosis (ATTR)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025

Congress Details

calander9-12 November, 2025 | United Kingdom

locationGlasgow, Scotland, United Kingdom

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Oral

Congress Materials

Health_quality_of_patients
icon Presentation Type
Poster
location icon Location
Glasgow, Scotland, United Kingdom
icon Title
Health-related quality of life for patients with transthyretin amyloid cardiomyopathy: A real-world study in Europe, Canada and Japan
Healthcare_Utilization
icon Presentation Type
Poster
location icon Location
Glasgow, Scotland, United Kingdom
icon Title
Healthcare resource utilisation for patients with transthyretin amyloid cardiomyopathy: A real-world study in Europe, Canada and Japan

Associated Materials

Transthyretin Amyloidosis (ATTR)

Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis

Journal of Clinical Medicine

Author(s)

Akash Singh, John Wyatt, Marie Théaudin, et al

September 2025

Preparation Date
March 2026
Job Code
MB-UK-00162

Transthyretin Amyloidosis (ATTR)

Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicentre Study

Annals of Medicine

Author(s)

Yessar Hussain, Saurabh Malhotra, Brett W. Sperry, et al

September 2025

Preparation Date
March 2026
Job Code
MB-UK-00163

Transthyretin Amyloidosis (ATTR)

Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B

Journal of the American College of Cardiology

Author(s)

Mathew S. Maurer, John L. Berk, Thibaud Damy, et al

August 2025

Preparation Date
March 2026
Job Code
MB-UK-00164

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Journal of the American College of Cardiology

Author(s)

Karola S. Jering, Marianna Fontana, Hicham Skali, et al

August 2025

Preparation Date
March 2026
Job Code
MB-UK-00165

Transthyretin Amyloidosis (ATTR)

Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial

Nature Medicine

Author(s)

Karola S. Jering, Marianna Fontana, Olivier Lairez, et al

August 2025

Preparation Date
March 2026
Job Code
MB-UK-00166

Transthyretin Amyloidosis (ATTR)

Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B

JACC: Advances

Author(s)

Ronald M. Witteles, Pablo Garcia-Pavia, Caroline Morbach, et al

August 2025

Preparation Date
March 2026
Job Code
MB-UK-00167
Preparation Date
March 2026
Job Code
MB-UK-00098